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rity (42%), patient confirmation accuracy (73%), the correct rate of administration 
time (47%) and the correct rate of drug administration (57%). More than half of 
pharmacists and nurses complain the system wasn’t stable (53%, 69%) and poor bar-
code sensitivity (47%, 64%). The ratio of medication error was significantly reduced. 
(0.18%±0.042%, 0.12%±0.039%, P value < 0.05, n= 12) From Oct 2nd to Nov 15th in 2012, 
we received 469 phone calls. The average of tracing call for drugs is 1.67 times every 
hour. ConClusions: Though some system problems may annoy hospital staffs, 
BCMA system could increase the accuracy of recognizing drugs, patients and tracing 
drugs. BCMA system also could significantly improve patient safety.
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objeCtives: ERP is the practice of using pharmaceutical prices in several countries 
to derive a price benchmark in a given country and could be used as the main 
criteria for pricing decisions or merely as supportive information. It is a widely 
used financing method worldwide and in Europe; by 2012, all EU-countries except 
UK and Sweden used ERP in some form. Turkey applies ERP as the main pricing 
criteria since 2004. This analysis aims to elaborate the Turkish ERP system with its 
effects on the countries referring Turkey. Methods: ERP systems of Turkey and 
countries referring Turkey have been analyzed. Results: Turkish reference basket 
is composed of Greece, Italy, France, Spain and Portugal, whose prices are rela-
tively lower than the European-average, plus import and manufacturer countries 
of the product. Lowest basket price sets the price-ceiling for reimbursed products, 
while highest can be taken for non-reimbursed products. Reference prices are sub-
ject to an exchange rate, fixed by Ministry of Health at approximately 40% below 
the actual rate. Consequently, Turkish prices are almost 44% of the lowest-priced 
European-country. Among the countries referring Turkey, Russia and S.Arabia are 
the most significant markets with their size and growing potentials. Additionally, 
Egypt, Macedonia, Morocco, Oman and Iran refer Turkey. ConClusions: Although 
countries referring Turkey have large reference baskets, low Turkish prices could still 
be considered as a suppressing factor on prices in these countries. Furthermore, 
significant price changes especially in Russia and S.Arabia would possibly cause 
a second wave in some CIS and Middle East countries respectively, as they would 
adjust their prices within 6-12 months accordingly. Multinational companies con-
sider this domino effect seriously and usually arrange launch sequencing to avoid 
inoperably-low-prices and secure the most-promising-markets. Consequently, 
innovative products’ price levels and availability might occasionally be affected 
negatively in Turkey and further in countries referring Turkey.
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objeCtives: In July 2012, the European Medicines Agency (EMA) established the 
Pharmacovigilance and Risk Assessment Committee (PRAC). The PRAC recommends 
and advises on any questions of pharmacovigilance activities related to a medi-
cine for human use and on risk management systems. This study describes PRAC’s 
activities to date. Methods: Meeting minutes since July 2012 were retrieved from 
the EMA website. The PRAC received questions attributed to seven categories: EU 
referral procedures for safety reasons, signals assessment and prioritization, risk 
management plans (RMPs), assessment of periodic safety update reports (PSURs), 
post-authorisation safety studies (PASS), product-related pharmacovigilance 
inspections, and other safety issues for discussion requested by the Committee 
for Medicinal Products for Human Use (CHMP) or Member States (MS). Results: 
There were 13 meeting minutes available (July 2012 – October 2013), containing1077 
questions/requests with/without a formal decision-making phase [149 (13.9%) in 
2012, 928 (86.2%) in 2013]. Three request types comprise nearly 80% (n= 860): signal 
assessment and prioritization [n= 140 (13%), 50 (4.7%) in 2012, 90 (8.4%) in 2013], 
RMPs [n= 416 (38.7%), 48 (4.5%) in 2012, 368 (34.2%) in 2013], and PSURs [n= 304 
(28.2%), 20 (1.8%) in 2012, 284 (26.4%) in 2013]. PRAC outputs were recommenda-
tions or advice. In 2012, there were 46 recommendations for 35 new signal assess-
ments requests. Recommendations regarding new signals were made either to the 
Marketing Authorization Holder (MAH) (n= 32) (e.g., submit a cumulative review of 
dermatomyositis within 30 days), the EMA (n= 6) (e.g., review cases of dermatomy-
ositis and report back), the PRAC rapporteur (n= 7) (e.g., assess the UK cases in the 
ongoing PSUR procedure) or the MS (n= 1) (e.g., UK to provide a report on the nicotinic 
receptor mutation). ConClusions: After an initial “running-in period”, the PRAC 
appears to be fulfilling its mandate. PRAC operations should be evaluated in terms 
of success (i.e., impact of decisions).
PHP122
tHe HistoriCal evolUtion of CHina’s drUg regUlatory system
Li H., Sun H.
Tianjin University, Tianjin, China
objeCtives: This article makes a review on the historical evolution of China’s drug 
regulatory system and provides some reflections and policy implications for the 
reform of the present system. Methods: This study is based on literature review 
and publicly available data by searching electronic databases and official web pages 
of Chinese government on the internet. Results: China’s drug regulatory system 
has experienced complicated process of evolution. During the period of planned 
economy China had no independent drug regulatory system. The way to control 
the quality and safety of pharmaceutical products was to take full control of every 
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objeCtives: Medication oversupply is an important problem which causes unnec-
essary avoidable health care costs. There are some studies determining magnitude 
and financial loss due to medication oversupply in western countries, they may not 
be applicable for Asia-pacific countries. This study aims to determine the preva-
lence, financial loss, and patterns of medication oversupply and factors associated 
with oversupply in Thailand. Methods: A retrospective database analysis was 
conducted. Patients visiting out-patient department of 3 hospitals and receiving 
at least 2 prescriptions within 6 months were included. The modified medication 
possession ratio (MPRm) was used to determine the medication supply. Patients 
having MPRm> 1.20 were defined as medication oversupply. The measures were 
prevalence of medication oversupply, the number of oversupplied medications, 
and financial loss due to medication oversupply. Analyses were stratified by type 
of hospitals. A mixed regression model was used to determine factors associated 
with prevalence medication oversupply. Results: A total of 99,743 patients were 
included. Patients were on average 49.7±21.2 years of age, 42.8% were male. Around 
13.4% of all patients had medication oversupply. Patients in regional hospital had 
higher prevalence of medication oversupply than patients in district hospital (13.8% 
VS 8.2%). Patients under civil servant medical benefit schemes (CSMBS) (13.6%) 
had the highest prevalence of medication oversupply. The total financial loss due 
to medication oversupply was $189,024 per year. The average financial loss due 
to medication oversupply was $1.9±19.0 per patient/year. Patients under CSMBS 
was highest average financial loss (2.6±23.2 $/patient/year). Age, gender, health 
insurance schemes, and number of medications the patients received were factors 
associated with medication oversupply. ConClusions: Medication oversupply is 
an important problem for the health system. Patients receiving care from regional 
hospital had higher likelihood of medication oversupply. Policy-makers may con-
sider developing policies for preventing medication oversupply.
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objeCtives: The recent reforms and policy changes have increased the cost pres-
sures on all health care stakeholders, including clinical experts. In the past, clini-
cal guidelines were developed independent of cost or economic considerations. 
However, increasingly, more clinical guidelines are mentioning cost concerns and 
referring to economic data in new recommendations. The objective of this study was 
to analyze trends in the use of health economic information for developing clinical 
guidelines. Methods: To understand trends in use of health economic informa-
tion we conducted targeted search for clinical guidelines, expert recommendations, 
and consensus statements with specific mention of “cost” or “economic” or related 
terms. A systematic literature search was undertaken for the databases Pubmed, 
Google Scholar and Cochrane. The guidelines published between 2003-2012 were 
included. For guidelines which met the search criteria, data was collected for the 
name of the authors, indication, year of publication, country/region, and context 
of use of cost/economic evidence. Results: Sixteen clinical guidelines published 
between 2003-2012 met the inclusion criteria for specific mention of cost/economic 
evidence. More than 50% of these guidelines were published between 2006-2012. For 
indication, 3 out of 16 guidelines were for diabetes, while the rest were for different 
indications. In these 16 guidelines “cost effectiveness” was mentioned 14 times, 
either referencing cost-effectiveness data or to mention the importance of such data 
for selecting treatment options. The guidelines commonly cite high cost of disease 
or high economic burden as one of the considerations for developing new recom-
mendations (11 out of 16). Another term that was commonly used by these guide-
lines was “cost-benefit,” which was mentioned 5 times in these guidelines. Notably, 
QALY was rarely mentioned (1 out of 16 times) in these guidelines. ConClusions: 
This analysis suggests that some clinical experts groups are increasingly showing 
willingness to use and incorporate health economic information for developing 
new recommendations
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objeCtives: To analyze the current usage of BCMA enforced by the pharmacists 
and nurses at a medical center in Taiwan, we collected data including of the overall 
system satisfaction, ratio of medication errors and phone calls for tracking stat 
drugs. Methods: The overall system’s satisfaction questionnaire for nurse (n= 89) 
and pharmacist (n= 30) was designed by 8 experts using content validity index (CVI). 
We have collected medication error ratio for one year in order to evaluate patients’ 
safety before and after using BCMA system. We also collected the numbers of phone 
calls for tracking stat drugs during Oct 2nd to Nov 15th in 2012. Results: In phar-
macists’ satisfaction questionnaire, they agree BCMA system can help them rec-
ognize drugs (60%), reduce medication errors (53%) and check drug delivery (90%). 
But they also think BCMA has increased workload (57%). In nurses’ satisfaction 
questionnaire, they agree BCMA system can help them increase case data’s integ-
